Document Detail


Detection of pancreatic adenocarcinoma using circulating fragments of fibrinogen.
MedLine Citation:
PMID:  20555269     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: There is an urgent need for biomarkers to detect pancreatic cancer in the early, potentially curable, stages.
METHODS: We have used SELDI profiling to analyze serum from 75 patients with pancreatic cancer and 61 patients with nonmalignant pancreaticobiliary diseases.
RESULTS: A peak in the SELDI spectra corresponding to a 53 residue fragment of the α-chain of fibrinogen is remarkably elevated in approximately 50% of the cancer patients. In addition, fibrinogen degradation products were measured using the DR-70 assay. The areas under the receiver operating characteristic curves for the SELDI-detected fibrinogen fragment, DR-70 and CA19-9 were 0.65, 0.75 and 0.86, respectively. Class prediction models using combinations of these markers did not increase the area under the receiver operating characteristic curve compared with CA19-9. The novel fibrinogen fragment was not elevated to the same extent in other malignancies but was elevated in some patients with benign pancreatic disease.
CONCLUSION: Both the SELDI-detected fragment of fibrinogen and DR-70 are significantly elevated in the serum of pancreatic cancer patients. However, they do not seem to improve pancreatic cancer detection over CA19-9 alone.
Authors:
Douglas G Ward; Wenbin Wei; John Buckels; Ahmed M I Taha; Bassem Hegab; Laura Tariciotti; Rasha Salih; Yi-Qun Qi; Ashley Martin; Philip J Johnson
Related Documents :
2078789 - Endoluminal ultrasound for the diagnosis and staging of pancreatic cancer.
6987959 - An appraisal of radical pancreatoduodenectomy based on glucagon secretion.
17912029 - Evaluation of gata-4 and gata-5 methylation profiles in human pancreatic cancers indica...
20300169 - Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, ...
15155719 - Reactive oxygen species produced by nad(p)h oxidase inhibit apoptosis in pancreatic can...
12499909 - Lipase supplementation therapy: standards, alternatives, and perspectives.
25034349 - Capture rate and representativity of the national prostate cancer register of sweden.
22899889 - A limited role of p53 on the ability of a hexane fraction of american ginseng to suppre...
15262119 - Modulation of cd3-zeta as a marker of clinical response to il-2 therapy in ovarian canc...
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  European journal of gastroenterology & hepatology     Volume:  22     ISSN:  1473-5687     ISO Abbreviation:  Eur J Gastroenterol Hepatol     Publication Date:  2010 Nov 
Date Detail:
Created Date:  2010-10-15     Completed Date:  2011-02-02     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9000874     Medline TA:  Eur J Gastroenterol Hepatol     Country:  England    
Other Details:
Languages:  eng     Pagination:  1358-63     Citation Subset:  IM    
Affiliation:
School of Cancer Sciences, University of Birmingham, Birmingham, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenocarcinoma / blood,  diagnosis*
Aged
CA-19-9 Antigen / blood*
England
Enzyme-Linked Immunosorbent Assay
Female
Fibrin Fibrinogen Degradation Products / analysis*
Humans
Male
Middle Aged
Pancreatic Neoplasms / blood,  diagnosis*
Predictive Value of Tests
Prospective Studies
ROC Curve
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
Tumor Markers, Biological / blood*
Up-Regulation
Chemical
Reg. No./Substance:
0/CA-19-9 Antigen; 0/Fibrin Fibrinogen Degradation Products; 0/Tumor Markers, Biological

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The H63D genetic variant of the HFE gene is independently associated with the virological response t...
Next Document:  Spontaneous hepatic rupture: 13-year experience of a single center.